| Literature DB >> 32337417 |
Chaitanya Kumar Thota1, Allison A Berger1, Laura Elomaa1, Chaunxiong Nie1, Christoph Böttcher2, Beate Koksch1.
Abstract
Multicomponent self-assembly of peptides is a powerful strategy to fabricate novel functional materials with synergetic properties that can be used for several nanobiotechnological applications. In the present study, we used a coassembly strategy to generate an injectable ultrashort bioactive peptide hydrogel formed by mixing a dipeptide hydrogelator with a macrophage attracting short chemotactic peptide ligand. Coassembly does not impede hydrogelation as shown by cryo-transmission electron microscopy (cryo-TEM), scanning electron microscopy, and rheology. Biocompatibility was shown by cytotoxicity assays and confocal microscopy. The hydrogels release the entrapped skin antibiotic ciprofloxacin, among others, in a slow and continuous manner. Such bioinspired advanced functional materials can find applications as wound dressing materials to treat chronic wound conditions like diabetic foot ulcer.Entities:
Year: 2020 PMID: 32337417 PMCID: PMC7178367 DOI: 10.1021/acsomega.9b04371
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1(A) Line structures of LΔF, fMLF isoniazid, ciprofloxacin, and amphotericin B. (B) Inversion test showing self-supporting hydrogels of LΔF alone (upper) and LΔF + fMLF (1:1) (lower) and cartoons of hydrogels and the nanofibers comprising them in each case. (C) Cryo-transmission electron microscopy (cryo-TEM) analysis of LΔF (upper) and LΔF + fMLF (1:1) (lower) hydrogels. (D) Time-dependent step-strain rheological tests of LΔF and LΔF + fMLF (1:0.5) showing injectability and self-healing properties. Confocal microscopy images showing viability of (E) U937 macrophages and (F) fibroblasts in 1% w/v LΔF + fMLF (1:0.5). (G) Monocyte/macrophage migration assay with untreated cells, LΔF alone, and 1% w/v LΔF + fMLF (1:0.25). (H) Release profiles for isoniazid, ciprofloxacin, and amphotericin B from 1% w/v LΔF + fMLF (1:0.25) hydrogel over a period of 5 days. (I) Release profile for ciprofloxacin from 0.5, 1, or 2% w/v LΔF + fMLF (1:0.25) hydrogel over a period of 5 days.